Blaze Bioscience
Blaze Bioscience develops imaging agents and imaging systems that provide surgeons with real-time, intraoperative visualization of tumor tissue during cancer surgery. Its lead technology, Tumor Paint and the investigational agent tozuleristide (BLZ-100), enables near-infrared fluorescence imaging to help surgeons distinguish cancer from healthy tissue in procedures for breast, brain, skin, and head and neck cancers. The organization aims to improve surgical outcomes for cancer patients by making tumor visualization more sensitive, reliable, and accessible.
Facts
- HQ
- Seattle, WA 98109, USA
- Sectors
- Biotechnology, Medical imaging, Healthcare
- Founded
- 2011 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Blaze Bioscience Inc Seattle business license
- Members see funding amounts. .
- Founders
- James Olson
Is this your organization? Claim it
GeekWire Awards 2020 Goes Virtual; Ally Wins Startup of the Year as Bill Gates and Celebrities Celebrate
GeekWire held a virtual GeekWire Awards livestream honoring top Pacific Northwest tech companies and leaders across 12 categories, with winners accepting via Zoom and special video messages from figures like Bill Gates. Seattle startup Ally won Startup of the Year, and the event included entertainment such as The Drunken Tenorperforming an "Opera di Zoom."
GeekWire to Host Virtual 2020 Awards July 23 Showcasing Pacific NW Finalists and Major Deals
The 2020 GeekWire Awards will be held as a virtual event at 4 p.m. on Thursday, July 23, featuring finalists across a dozen categories from Pacific Northwest tech and sponsored by Wave Business with proceeds supporting Technology Access Foundation. The article reviews finalists (e.g., Ally, Armoire, LevelTen Energy) and notable deals (including Adaptive Biotechnologies IPO and Assurance’s $2.35B acquisition) ahead of the livestream show.
Athira Pharma raises $85M Series B to push NDX-1017 toward FDA approval for Alzheimer’s, Parkinson’s and ALS
Seattle biotech Athira Pharma raised $85 million in a Series B round to advance NDX-1017, a regenerative therapy aimed at halting or reversing nerve damage in Alzheimer’s, Parkinson’s and ALS, with preliminary trial results reported as positive and potential market availability in 2–3 years.
See all 4 stories, episodes and videos about Blaze Bioscience.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Steven Daly Executive, Executive Officer, Director, President & Chief Executive Officer